

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma [ID1166]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No valid equality issues were raised during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The committee noted concerns from clinical experts that tisagenlecleucel-T may have access issues compared to current treatment as it is only able to be provided at specialist centres. The commissioning expert from NHS England confirmed that treatment would take place in accredited transplant centres which are well distributed across England. The commissioning expert also confirmed that national MDTs would be set up to ensure equality of referral and treatment access. The committee concluded that this was not a specific equality issue.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The company highlighted that tisagenlecleucel-T would more likely be used for males and for older people due to the epidemiology of the disease. The committee noted that the CORAL extension study excluded patients aged over 65 years and agreed there was a lack of data for this age group. The committee did not consider these to be specific equality issues because the recommendation for tisagenlecleucel-T is for the whole population in the anticipated marketing authorisation. The committee agreed that its recommendations do not have a different impact on people protected by the equality legislation than on the wider population.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

See section 3.19 in the appraisal consultation document

Approved by Associate Director (name):Frances Sutcliffe.....

Date: 07/09/2018

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No further issues were identified during consultation

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No the recommendations apply to the full population in the marketing authorisation

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No the recommendations apply to the full population in the marketing authorisation

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No the recommendations apply to the full population in the marketing authorisation

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes see section 3.23 of the final appraisal determination

Approved by Associate Director (name): Jasdeep Hayre

Date: 25/01/2019